This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): BMS-275291
Description: BMS-275291 is a sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. BMS-275291 selectively inhibits several MMPs (MMP 1, 2, 8, 9, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.
Deal Structure: In February 1998, Celltech Group (through Chiroscience) entered into a collaboration arrangement with Bristol Myers Squibb. Pursuant to the agreement, BMS licensed from Celltech the rights to Celltech's Matrix Metalloprotease inhibitors (MMPIs). The collaboration provides that BMS would undertake the development of MMPIs in the field of oncology and Celltech would receive milestones and royalties on successful development and launch of any product.
In 2004, UCB acquired Celltech.
Partners: UCB SA
Additional information available to subscribers only: